2026-04-29T20:01:07Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/253662025-12-18T13:00:57Zcom_20.500.12105_2327com_20.500.12105_2290col_20.500.12105_16991

00925njm 22002777a 4500 dc Patton, E Elizabeth author Mueller, Kristen L author Adams, David J author Anandasabapathy, Niroshana author Aplin, Andrew E author Bertolotto, Corine author Bosenberg, Marcus author Ceol, Craig J author Burd, Christin E author Chi, Ping author Herlyn, Meenhard author Holmen, Sheri L author Karreth, Florian A author Kaufman, Charles K author Khan, Shaheen author Kobold, Sebastian author Leucci, Eleonora author Levy, Carmit author Lombard, David B author Lund, Amanda W author Marie, Kerrie L author Marine, Jean-Christophe author Marais, Richard author McMahon, Martin author Robles-Espinoza, Carla Daniela author Ronai, Ze'ev A author Samuels, Yardena author Soengas, MS author Villanueva, Jessie author Weeraratna, Ashani T author White, Richard M author Yeh, Iwei author Zhu, Jiyue author Zon, Leonard I author Hurlbert, Marc S author Merlino, Glenn author 2021-05-10 There is a lack of appropriate melanoma models that can be used to evaluate the efficacy of novel therapeutic modalities. Here, we discuss the current state of the art of melanoma models including genetically engineered mouse, patient-derived xenograft, zebrafish, and ex vivo and in vitro models. We also identify five major challenges that can be addressed using such models, including metastasis and tumor dormancy, drug resistance, the melanoma immune response, and the impact of aging and environmental exposures on melanoma progression and drug resistance. Additionally, we discuss the opportunity for building models for rare subtypes of melanomas, which represent an unmet critical need. Finally, we identify key recommendations for melanoma models that may improve accuracy of preclinical testing and predict efficacy in clinical trials, to help usher in the next generation of melanoma therapies. Cancer Cell . 2021 May 10;39(5):610-631 https://pmc.ncbi.nlm.nih.gov/articles/PMC8378471/pdf/nihms-1689188.pdf 33545064 https://hdl.handle.net/20.500.12105/25366 animal models drug discovery immunotherapy melanoma targeted therapy therapeutics tumor microenvironment Melanoma models for the next generation of therapies.